December 2, 2022
Loading...
You are here:  Home  >  Banking & Finance  >  Current Article

Amgen looks for new life with Micromet

IN THIS ARTICLE

As Thousand Oaks-based Amgen prepares to spend $1.2 billion to buy leukemia drug maker Micromet, there are early signs that revenue from some of its biggest-selling drugs are stabilizing after years of declines and that biosimilars might present as much of an opportunity as a threat. Amgen, the world’s largest biotech company, said Jan. 26…

Subscribe

    This article is only available to Business Times subscribers
  • Subscribers: or REGISTER for complete digital access.
  • Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
  • Check the STATUS of your Subscription Account.